Evidence map›Paper›PMID 25537021›Full record

ArticleNeuro-oncology2015

Cytogenetic landscape of paired neurospheres and traditional monolayer cultures in pediatric malignant brain tumors.

Xiumei Zhao, Yi-Jue Zhao, Qi Lin, Litian Yu, Zhigang Liu, Holly Lindsay, Mari Kogiso, Pulivarthi Rao, Xiao-Nan Li, Xinyan Lu

Open access · bronzeAbstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it

0cells of the map it votes in

14citing papers in PubMed

0.3field-weighted citation impact, top 36% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026
Review
Current Landscape of Preclinical Models for Pediatric Gliomas: Clinical Implications and Future Directions.Cancers · 2025
Review
Direct Implantation of Patient Brain Tumor Cells into Matching Locations in Mouse Brains for Patient-Derived Orthotopic Xenograft Model Development.Cancers · 2024
Article
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations.Cancers · 2024
Review
Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas.Nature communications · 2022
Article
Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
Article
Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors.Cancer letters · 2020
Article
Hypoxic Environment and Paired Hierarchical 3D and 2D Models of PediatricCancers · 2019
Article
G-quadruplex ligand RHPS4 radiosensitizes glioblastoma xenograft in vivo through a differential targeting of bulky differentiated- and stem-cancer cells.Journal of experimental & clinical cancer research : CR · 2019
Article
Patient-Derived Orthotopic Xenograft Models of Pediatric Brain Tumors: In a Mature Phase or Still in Its Infancy?Frontiers in oncology · 2019
Review
Preclinical Models of Pediatric Brain Tumors-Forging Ahead.Bioengineering (Basel, Switzerland) · 2018
Review
Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
Article
In vitro formation of neuroclusters in microfluidic devices and cell migration as a function of stromal-derived growth factor 1 gradients.Cell adhesion & migration · 2017
Article
Therapeutic potential of cancer stem cells.Medical oncology (Northwood, London, England) · 2015
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiumei ZhaoLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Yi-Jue ZhaoLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Qi LinLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Litian YuLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Zhigang LiuLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Holly LindsayLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Mari KogisoLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Pulivarthi RaoLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Xiao-Nan LiLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

Xinyan LuLaboratory of Molecular Neuro-Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (X.Z., Q.L., L.Y., Z.L., H.L., M.K., X.-N.L.); Molecular Cytogenetics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas (Y.-J.Z., P.R., X.L.); Laboratory of Clinical Cytogenetics, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (X.L.).

The University of Texas MD Anderson Cancer Center · USChildren's Cancer Center · USBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew therapeutic targets are needed to eliminate cancer stem cells (CSCs). We hypothesize that direct comparison of paired CSCs and nonstem tumor cells (NSTCs) will facilitate identification of primary "driver" chromosomal aberrations that can serve as diagnostic markers and/or therapeutic targets.

methodsWe applied spectral karyotyping and G-banding to matched pairs of neurospheres (CSC-enriched cultures) and fetal bovine serum-based monolayer cultures (enriched with NSTCs) from 16 patient-derived orthotopic xenograft mouse models, including 9 medulloblastomas (MBs) and 7 high-grade gliomas (HGGs), followed by direct comparison of their numerical and structural abnormalities.

resultsChromosomal aberrations were detected in neurospheres of all 16 models, and 82.0% numerical and 82.4% structural abnormalities were maintained in their matching monolayer cultures. Among the shared abnormalities, recurrent clonal changes were identified including gain of chromosomes 18 and 7 and loss of chromosome 10/10q (5/16 models), isochromosome 17q in 2 MBs, and a new breakpoint of 13q14 in 3 HGGs. Chromothripsis-like evidence was also observed in 3 HGG pairs. Additionally, we noted 20 numerical and 15 structural aberrations that were lost from the neurospheres and found 26 numerical and 23 structural aberrations that were only present in the NSTCs. Compared with MBs, the neurosphere karyotypes of HGG were more complex, with fewer chromosomal aberrations preserved in their matching NSTCs.

conclusionSelf-renewing CSCs in MBs and pediatric HGGs harbor recurrent numerical and structural aberrations that were maintained in the matching monolayer cultures. These primary chromosomal changes may represent new markers for anti-CSC therapies.

Indexed as

Chromosome AberrationsAdolescentAnimalsBrain NeoplasmsCattleCell Line, TumorCerebellar NeoplasmsChildChild, PreschoolCytogenetic AnalysisFemaleGliomaHumansInfantMaleMedulloblastomaSerum Albumin, Bovinecancer stem cellchromosomal aberrationneurosphereorthotopic xenograft model

Identifiers

PMID25537021

DOI10.1093/neuonc/nou337

PMCPMC5654349

OpenAlexW2168786243

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.